Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Thomas Weaver | M | - |
PetMedix Ltd.
 PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | 6 jaar |
| Timothy James Rink | M | 78 |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Erwin Boos | M | 46 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Alf Gunnar Martin Nicklasson | M | 69 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 7 jaar |
| Alan Bradley | M | 64 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | - |
| Tan Li | F | 60 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Christian Itin | M | 59 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Timothy Nigel Carl Wells | M | 62 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Simone Song | F | 59 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Jolyon Martin | M | 53 |
PetMedix Ltd.
PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | 6 jaar |
| Douglas Fearon | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Volker Germaschewski | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Samuel Bjork | M | - |
PetMedix Ltd.
PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | - |
| Fabian Kausche | M | - |
PetMedix Ltd.
PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | 5 jaar |
| Alastair Kilgour | M | - |
PetMedix Ltd.
PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | - |
| Robert Tansley | M | 61 |
PetMedix Ltd.
PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | - |
| Jasper Clube | M | 56 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Nigel Clark | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Glenn Alfons Friedrich | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Paul Kellam | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Kirk Chin Kee | M | 62 |
University of Cambridge
| 8 jaar |
| Luca Anderlini | M | 66 |
University of Cambridge
| 5 jaar |
| Jean-Michel Cossery | M | 65 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | 3 jaar |
| Anne Philomena Hyland | F | 64 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 6 jaar |
| R. Dominic King-Smith | M | - |
University of Cambridge
| 7 jaar |
| Simon Sturge | M | 65 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 2 jaar |
| Martin Roper | M | 61 |
University of Cambridge
| 5 jaar |
| Alastair K. Livesey | M | 67 |
University of Cambridge
| 3 jaar |
| Jonathan Mark Huntley | M | - |
University of Cambridge
| 8 jaar |
| Teck Huat Tan | M | 63 |
University of Cambridge
| 4 jaar |
| Khaled Asad Nasr | M | 66 |
University of Cambridge
| 3 jaar |
| Hugh Anthony Simons | M | - |
University of Cambridge
| 3 jaar |
| Mark Borwick | M | - |
University of Cambridge
| 3 jaar |
| John Simon Hunt | M | 61 |
University of Cambridge
| 4 jaar |
| Geoffrey G. Davis | M | - |
University of Cambridge
| 7 jaar |
| Hwee Hua Lim | F | 65 |
University of Cambridge
| 6 jaar |
| Paula Disberry | F | 56 |
University of Cambridge
| 5 jaar |
| Michael Owen | M | 73 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 1 jaar |
| Kin Wah Mak | M | 67 |
University of Cambridge
| 4 jaar |
| Michael John Wilson | M | - |
University of Cambridge
| 8 jaar |
| Ram shenoy | M | - |
University of Cambridge
| 3 jaar |
| Anthony Ian Walker | M | - |
University of Cambridge
| 6 jaar |
| Tony Alves | M | 62 |
University of Cambridge
| 6 jaar |
| Chong Kiat Lim | M | 68 |
University of Cambridge
| 7 jaar |
| Andrew Peter Sandham | M | 69 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Beatriz Pessoa de Araujo | F | - |
University of Cambridge
| 7 jaar |
| David Chiswell | M | 70 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 4 jaar |
| Roy Merritt | M | 60 |
University of Cambridge
| 4 jaar |
| Julian Healy | M | 62 |
University of Cambridge
| 5 jaar |
| Christian Gröndahl | M | 60 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
| Paul J. Carter | M | - |
University of Cambridge
| 8 jaar |
| Angus Porter | M | 67 |
University of Cambridge
| 4 jaar |
| Gerard Evan | M | - |
University of Cambridge
| 4 jaar |
| Matthew J. K. Hickman | M | 60 |
University of Cambridge
| 4 jaar |
| Alan Cullens | M | 60 |
University of Cambridge
| 3 jaar |
| Kwok-Kuen Leong | M | 63 |
University of Cambridge
| 4 jaar |
| Dame Anne Glover | M | - |
University of Cambridge
| 3 jaar |
| Tun Ho Kwok | M | 61 |
University of Cambridge
| 4 jaar |
| Simon Rendell | M | 62 |
University of Cambridge
| 3 jaar |
| Jonathan Treherne | M | 62 |
University of Cambridge
| 3 jaar |
| Timothy Clissold | M | 64 |
University of Cambridge
| 4 jaar |
| Zainun binti Ali | F | 72 |
University of Cambridge
| 3 jaar |
| John Davison | M | - |
University of Cambridge
| 4 jaar |
| Kate Mingay | F | - |
University of Cambridge
| 3 jaar |
| Alison Beckett | F | 62 |
University of Cambridge
| 3 jaar |
| Paul Lyristis | M | - |
University of Cambridge
| 3 jaar |
| Nick Goddard | M | - |
University of Cambridge
| 3 jaar |
| Yiannis Petrides | M | 66 |
University of Cambridge
| 4 jaar |
| Jem Davies | M | - |
University of Cambridge
| 3 jaar |
| James Witter | M | - |
University of Cambridge
| 3 jaar |
| Edwin Tai Chiu Cheng | M | 67 |
University of Cambridge
| 3 jaar |
| Shoong Tat Cheng | M | 63 |
University of Cambridge
| 4 jaar |
| Peter Jacobs | M | 62 |
University of Cambridge
| 4 jaar |
| Robert Charles Standing | M | 64 |
University of Cambridge
| 4 jaar |
| Stuart John Dootson | M | 57 |
University of Cambridge
| 4 jaar |
| Howard Chase | M | 70 |
University of Cambridge
| 22 jaar |
| Timothy Farazmand | M | 64 |
University of Cambridge
| 3 jaar |
| Fiona Claire Reynolds | F | 66 |
University of Cambridge
| 1 jaar |
| Osvaldo Pitters | M | - |
University of Cambridge
| 1 jaar |
| James Anthony McNaught-Davis | M | 65 |
University of Cambridge
| 2 jaar |
| David E. Gill | M | - |
University of Cambridge
| 4 jaar |
| Simon Williams | M | - |
University of Cambridge
| 3 jaar |
| Thomas J. Farrell | M | 60 |
University of Cambridge
| 4 jaar |
| Jim Warwick | M | 59 |
University of Cambridge
| 2 jaar |
| Ivo Coulson | M | 59 |
University of Cambridge
| 4 jaar |
| James William Buckie | M | 63 |
University of Cambridge
| 3 jaar |
| A. David Nickols | M | 64 |
University of Cambridge
| 1 jaar |
| Robert Fishleigh | M | - |
University of Cambridge
| 3 jaar |
| David Checkel | M | - |
University of Cambridge
| 2 jaar |
| Stella David | F | 61 |
University of Cambridge
| 4 jaar |
| Richard V. Penty | M | - |
University of Cambridge
| 4 jaar |
| Michael Lacovara | M | 60 |
University of Cambridge
| 1 jaar |
| David Godden | M | - |
University of Cambridge
| 4 jaar |
| Gehan Anil Joseph Amaratunga | M | - |
University of Cambridge
| 3 jaar |
| Adrian Blumfield | M | - |
University of Cambridge
| 3 jaar |
| Chuan Thye Kho | M | 56 |
University of Cambridge
| 4 jaar |
| Marcus Thompson | M | - |
University of Cambridge
| 3 jaar |
| Christopher A. Grew | M | - |
University of Cambridge
| 4 jaar |
| Stephen Riley | M | - |
University of Cambridge
| 4 jaar |
| Clive Swan | M | - |
University of Cambridge
| 4 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigd Koninkrijk | 100 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Allan Bradley
- Persoonlijk netwerk